

**The Chinese American Medical Association of Southern California (CAMASC)
proudly presents a continuing medical education activity on**

“Same Diseases, Different Continents”

CME Activity I

Sunday, March 17, 2013

The Langham Hotel Hong Kong

8 Peking Road, Tsimshatsui, Kowloon, Hong Kong

Program Overview

As China modernizes and lifestyles change, the Chinese population in China and the United States faces a common spectrum of health problems. These illnesses include hepatitis B, diabetes, cardiovascular disease, cancer, psychiatric and neurological illnesses. Hepatitis B is highly prevalent, and cancer treatment and preventions constitute major management challenges as the Chinese population ages. Furthermore, cancer is the leading cause of preventable deaths in the Chinese population. This situation also applies to Overseas Chinese populations situated in countries such as the United States, particularly in Southern California where the Chinese immigrant population has been growing rapidly in the last decade.

These considerations suggest gaps in knowledge in how common diseases in similar populations of Chinese patients are managed in different continents at the primary care level. Comparisons are especially appropriate now as the medical system in East Asia has advanced and become comparable to those in Western countries, and as East Asian quality improvement methodology has matured. These intercontinental gaps are in addition to the gaps caused by the development and application of new disease specific knowledge to improve patient outcomes, and differ from cultural competence gaps identified in the United States.

The theme in this meeting is to highlight new treatments for cancers that are more prevalent in the United States. While chronic myelogenous leukemia, breast cancer and prostate cancer have been less prevalent, the incidence of these conditions has been rising in East Asia. Melanoma is also less common, but not any less deadly in East Asia. The new advances in treatment will therefore be of great interest to medical practitioners. Underlying these advances has been the development of a new class of medications, tyrosine kinase inhibitors. Working by a totally different mechanism, these agents have had a revolutionary impact in oncology, and are likely to find many more applications in the future. A review of the unique features of this class of medications is appropriate as the primary care provider will be encountering patients on these medications.

This educational meeting is needed to discover whether there are gaps in intercontinental medical knowledge, in addition to addressing gaps in disease-related knowledge, competence, and performance. This will be a live educational forum which will allow our community physicians from Southern California to meet and have an open dialogue with conference lecturers from the United States and China on different approaches to disease management and treatment options that are also culturally sensitive, the goal of which is to improve knowledge, competence, and performance for better patient care.

Target Audience

The target audience for this CME activity will consist of physician members of CAMASC and non-members who primarily serve the Chinese population in the Los Angeles Basin and surrounding areas in Southern California and other Chinese populated regions, which includes family practice and internal medicine physicians, physicians of all other medical specialties, and physicians-in-training.

Accreditation Statement



The Chinese American Medical Association of Southern California (CAMASC) is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The Chinese American Medical Association of Southern California (CAMASC) takes responsibility for the content, quality and scientific integrity of this CME activity.

Credit Designation Statement

The Chinese American Medical Association of Southern California (CAMASC) designates this live activity for a maximum of *pending 5.0 AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

Educational Method

The conference will consist of five (5) live lectures, presented by distinguished faculty to facilitate the different educational needs of a diverse audience. The activity will employ a combination of educational methods, including live didactic lectures, case studies, and interactive techniques such as group discussions, question/answer sessions, post-activity evaluations, and 2-month follow-up evaluations.

All attendees will be asked to complete the post-activity evaluations online within 3 weeks in order to receive certificates of CME credit.

California Assembly Bill (AB) 1195

This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curricula in the subjects of cultural and linguistic competency.

Commercial Support

This activity may be funded, in part, by grant and exhibit fees from commercial interests, in compliance with the Accreditation Council for Continuing Medical Education (ACCME) and the Institute for Medical Quality/ California Medical Association (IMQ/CMA) standards and guidelines. As of this webpage publishing, a complete listing of commercial supporters was not available. Detailed disclosures will be made to the participants in accordance to the accreditation standard and appropriate acknowledgment will be given to all supporters prior to the CME presentation begins at this activity.

Disclosure Statement

As a CME provider accredited by IMQ/CMA, CAMASC must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control or deliver the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty will also disclose any off-label and/or investigative use of pharmaceuticals or instruments discussed in their presentation. Detailed disclosures will be made at this activity prior to the CME presentations and on course materials.

Americans with Disabilities Act

CAMASC complies with the Americans with Disabilities Act. Please contact our CME Administrator at 213-572-0631 or camasc@foundationpamc.org no later than Friday, March 1, 2013. Every reasonable effort will be made to accommodate your special needs.

Conference Agenda – For CME Activity I

Date: Sunday, March 17, 2013

Location: Langham Hotel
8 Peking Road, Tsimshatsui
Kowloon, Hong Kong
China

8:30 AM Registration

9:30AM Opening Remarks / Disclosure

10:00AM Systemic Treatment of Melanoma
Faculty – Michael K Wong, M.D., Ph.D.

Purpose

To manage patients with the new agents in melanoma

Objectives

- Describe the presentation of melanoma in Chinese patients
- Select treatment options for metastatic melanoma
- Distinguish each of the 3 drugs by mechanisms of action and use

11:00AM Treatments for Prostate Cancer
Faculty – Richard Lo, M.D.

Purpose

To decrease knowledge, competence, and practice gaps regarding new medications for the treatment of metastatic prostate cancer

Objectives

- Integrate these new medications into the current management of castrate resistant prostate cancer
- Differentiate between these three newly approved drugs by indications, risks and benefits

12:00PM Lunch

1:00PM Therapy for Breast Cancer
Faculty – Kevin Loh, M.D.

Purpose

To review two new areas in the treatment of breast cancer. One is a new medication called pertuzumab, and the other is a newly recognized side effect of aromatase inhibitors

Objectives

- Educate patients about the indications, risks and benefits of pertuzumab.
- Implement screening for the Aromatase Inhibitor Musculoskeletal Syndrome in patients who are taking aromatase inhibitors

2:00PM Recognition of Tyrosine Kinase Inhibitors Toxicity
Faculty – Chun-Key Law, M.D.

Purpose

To reduce the knowledge, competence and practice gaps in recognizing side effects of tyrosine kinase inhibitors through increased physician awareness

Objective

- Identify cancers where tyrosine kinase inhibitors are used
- Identify non-cancerous diagnoses where tyrosine kinase inhibitors are being studied.
- Diagnose common side effects of tyrosine kinase inhibitors (rash, hypertension, hypothyroidism, hyperlipidemia)
- Identify uncommon side effects of tyrosine kinase inhibitors (bleeding, thromboembolic phenomena)

3:00 PM Treatment of Chronic Myelogenous Leukemia
Faculty – Au Wing Yan, M.D.

Purpose

To provide the practitioner with the ability to explain how tyrosine kinase inhibitors work in CML and to choose between them

Objective

- Diagnose chronic myelogenous leukemia
- Monitor the status and treatment response of chronic myelogenous leukemia
- Select treatments for chronic myelogenous leukemia at different stages of the disease

4:00 PM Closing Remarks

CAMASC reserves the right to make changes wherever deemed necessary.